226 related articles for article (PubMed ID: 20139275)
21. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
Oshikawa K; Rakhmilevich AL; Shi F; Sondel PM; Yang N; Mahvi DM
Hum Gene Ther; 2001 Jan; 12(2):149-60. PubMed ID: 11177552
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice.
Uemura A; Takehara T; Miyagi T; Suzuki T; Tatsumi T; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Immunol Immunother; 2010 Mar; 59(3):453-63. PubMed ID: 19756594
[TBL] [Abstract][Full Text] [Related]
23. Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice.
Kishida T; Asada H; Itokawa Y; Yasutomi K; Shin-Ya M; Gojo S; Cui FD; Ueda Y; Yamagishi H; Imanishi J; Mazda O
Mol Ther; 2003 Nov; 8(5):738-45. PubMed ID: 14599806
[TBL] [Abstract][Full Text] [Related]
24. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
25. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
[TBL] [Abstract][Full Text] [Related]
26. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice.
Kishida T; Asada H; Satoh E; Tanaka S; Shinya M; Hirai H; Iwai M; Tahara H; Imanishi J; Mazda O
Gene Ther; 2001 Aug; 8(16):1234-40. PubMed ID: 11509956
[TBL] [Abstract][Full Text] [Related]
27. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
[TBL] [Abstract][Full Text] [Related]
28. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice.
Kramer MG; Masner M; Casales E; Moreno M; Smerdou C; Chabalgoity JA
BMC Cancer; 2015 Sep; 15():620. PubMed ID: 26347489
[TBL] [Abstract][Full Text] [Related]
30. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
[TBL] [Abstract][Full Text] [Related]
31. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy.
Torrero MN; Henk WG; Li S
Clin Cancer Res; 2006 Jan; 12(1):257-63. PubMed ID: 16397050
[TBL] [Abstract][Full Text] [Related]
32. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma.
Lucas ML; Heller L; Coppola D; Heller R
Mol Ther; 2002 Jun; 5(6):668-75. PubMed ID: 12027550
[TBL] [Abstract][Full Text] [Related]
33. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.
Kaiga T; Sato M; Kaneda H; Iwakura Y; Takayama T; Tahara H
J Immunol; 2007 Jun; 178(12):7571-80. PubMed ID: 17548592
[TBL] [Abstract][Full Text] [Related]
34. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody.
Rakhmilevich AL; Hooper AT; Hicklin DJ; Sondel PM
Mol Cancer Ther; 2004 Aug; 3(8):969-76. PubMed ID: 15299079
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression.
Miller G; Bleier JI; Antonescu C; Pillarisetty VG; Shah AB; Lahrs S; DeMatteo RP
Int J Cancer; 2004 Jun; 110(3):395-402. PubMed ID: 15095305
[TBL] [Abstract][Full Text] [Related]
36. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
[TBL] [Abstract][Full Text] [Related]
37. Chitosan nanoparticle-based delivery of fused NKG2D-IL-21 gene suppresses colon cancer growth in mice.
Tan L; Han S; Ding S; Xiao W; Ding Y; Qian L; Wang C; Gong W
Int J Nanomedicine; 2017; 12():3095-3107. PubMed ID: 28450784
[TBL] [Abstract][Full Text] [Related]
38. Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death.
Melero I; Gabari I; Tirapu I; Arina A; Mazzolini G; Baixeras E; Feijoo E; Alfaro C; Qian C; Prieto J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3546-54. PubMed ID: 14506140
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
40. Using genetically modified microvascular free flaps to deliver local cancer immunotherapy with minimal systemic toxicity.
Dempsey MP; Hamou C; V JM; Ghali S; Jazayeri L; Grogan RH; Gurtner GC
Plast Reconstr Surg; 2008 May; 121(5):1541-1553. PubMed ID: 18453976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
